Wall Street analysts expect that RedHill Biopharma Ltd – (NASDAQ:RDHL) will report sales of $2.14 million for the current fiscal quarter, according to Zacks Investment Research. Two analysts have issued estimates for RedHill Biopharma’s earnings, with the highest sales estimate coming in at $2.40 million and the lowest estimate coming in at $1.89 million. The business is scheduled to report its next quarterly earnings results on Wednesday, May 2nd.
According to Zacks, analysts expect that RedHill Biopharma will report full year sales of $2.14 million for the current year, with estimates ranging from $9.42 million to $113.90 million. For the next financial year, analysts expect that the business will post sales of $59.16 million per share, with estimates ranging from $15.00 million to $141.40 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of research analysts that follow RedHill Biopharma.
RedHill Biopharma (NASDAQ:RDHL) last announced its quarterly earnings data on Thursday, February 22nd. The biotechnology company reported ($0.50) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.65) by $0.15. The business had revenue of $2.00 million during the quarter, compared to analysts’ expectations of $1.89 million.
A number of brokerages have weighed in on RDHL. HC Wainwright reaffirmed a “buy” rating and issued a $36.00 price objective on shares of RedHill Biopharma in a report on Tuesday, November 21st. Zacks Investment Research raised RedHill Biopharma from a “hold” rating to a “buy” rating and set a $5.50 price objective on the stock in a report on Friday, November 17th. Nomura began coverage on RedHill Biopharma in a report on Friday, January 26th. They issued a “buy” rating and a $18.00 price objective on the stock. Finally, Roth Capital lowered their price objective on RedHill Biopharma from $27.00 to $20.00 and set a “buy” rating on the stock in a report on Tuesday, November 14th. One research analyst has rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the company. RedHill Biopharma currently has an average rating of “Buy” and an average price target of $19.70.
Several hedge funds have recently bought and sold shares of RDHL. 683 Capital Management LLC acquired a new stake in shares of RedHill Biopharma during the 4th quarter valued at approximately $5,136,000. Creative Planning acquired a new stake in shares of RedHill Biopharma during the 4th quarter valued at approximately $722,000. Virtu Financial LLC acquired a new stake in shares of RedHill Biopharma during the 4th quarter valued at approximately $312,000. Meitav Dash Investments Ltd. acquired a new stake in shares of RedHill Biopharma during the 4th quarter valued at approximately $244,000. Finally, Citadel Advisors LLC acquired a new stake in shares of RedHill Biopharma during the 4th quarter valued at approximately $170,000. Institutional investors own 15.97% of the company’s stock.
Shares of RedHill Biopharma (RDHL) traded down $0.28 on Friday, reaching $5.84. The company’s stock had a trading volume of 66,195 shares, compared to its average volume of 111,829. RedHill Biopharma has a 12 month low of $4.30 and a 12 month high of $11.25. The stock has a market cap of $130.19, a price-to-earnings ratio of -2.34 and a beta of 0.53.
COPYRIGHT VIOLATION NOTICE: “Zacks: Analysts Anticipate RedHill Biopharma Ltd – (RDHL) Will Announce Quarterly Sales of $2.14 Million” was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece of content on another website, it was copied illegally and republished in violation of US & international copyright laws. The correct version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/03/19/zacks-analysts-anticipate-redhill-biopharma-ltd-rdhl-will-announce-quarterly-sales-of-2-14-million.html.
About RedHill Biopharma
Redhill Biopharma Ltd, is an Israel-based specialty biopharmaceutical company. The Company focuses on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for the treatment of gastrointestinal and inflammatory diseases and cancer. It offers the following gastrointestinal products in the United States: Donnatal, a prescription oral adjunctive drug used in the treatment of Irritable Bowel Syndrome (IBS) and acute enterocolitis, as well as EnteraGam, a medical food intended for the dietary management, under medical supervision, of chronic diarrhea and loose stools.
Get a free copy of the Zacks research report on RedHill Biopharma (RDHL)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for RedHill Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RedHill Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.